Search hospitals > Connecticut > Hartford
Connecticut Children's Medical Center
Claim this profileHartford, Connecticut 06106
Global Leader in Leukemia
Global Leader in Tumors
Conducts research for Neuroblastoma
Conducts research for Lymphoblastic Leukemia-Lymphoma
Conducts research for Acute Lymphoblastic Leukemia
315 reported clinical trials
17 medical researchers
Summary
Connecticut Children's Medical Center is a medical facility located in Hartford, Connecticut. This center is recognized for care of Leukemia, Tumors, Neuroblastoma, Lymphoblastic Leukemia-Lymphoma, Acute Lymphoblastic Leukemia and other specialties. Connecticut Children's Medical Center is involved with conducting 315 clinical trials across 506 conditions. There are 17 research doctors associated with this hospital, such as Michael S. Isakoff, Jeffrey Hyams, Andrea Orsey, and Donna Boruchov.Area of expertise
1Leukemia
Global LeaderStage II
Stage IV
Stage III
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Michael S. IsakoffConnecticut Children's Medical Center7 years of reported clinical research
Expert in Tumors
Expert in Neuroblastoma
59 reported clinical trials
117 drugs studied
Jeffrey HyamsConnecticut Children's Medical Center3 years of reported clinical research
Studies Crohn's Disease
Studies Inflammatory Bowel Disease
6 reported clinical trials
2 drugs studied
Andrea OrseyConnecticut Children's Medical Center3 years of reported clinical research
Studies Quality of Life
Studies Lymphoblastic Leukemia-Lymphoma
4 reported clinical trials
15 drugs studied
Donna BoruchovConnecticut Children's Medical Center5 years of reported clinical research
Studies Sickle Cell Anemia
Studies Sickle Cell Disease
3 reported clinical trials
5 drugs studied
Clinical Trials running at Connecticut Children's Medical Center
Brain Tumor
Langerhans Cell Histiocytosis
Osteosarcoma
Ulcerative Colitis
Astrocytoma
Germ Cell Tumors
Rhabdomyosarcoma
Neuroblastoma
Crohn's Disease
Non-Hodgkin's Lymphoma
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Selumetinib vs Carboplatin/Vincristine
for Brain Cancer
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether selumetinib works better in treating patients with NF1-associated low-grade glioma compared to standard therapy with carboplatin and vincristine.
Recruiting2 awards Phase 328 criteria
Selumetinib + Vinblastine
for Low-Grade Glioma
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth by stopping cell division and may kill cancer cells. Giving selumetinib in combination with vinblastine may work better than selumetinib alone in treating recurrent or progressive low-grade glioma.
Recruiting2 awards Phase 339 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Connecticut Children's Medical Center?
Connecticut Children's Medical Center is a medical facility located in Hartford, Connecticut. This center is recognized for care of Leukemia, Tumors, Neuroblastoma, Lymphoblastic Leukemia-Lymphoma, Acute Lymphoblastic Leukemia and other specialties. Connecticut Children's Medical Center is involved with conducting 315 clinical trials across 506 conditions. There are 17 research doctors associated with this hospital, such as Michael S. Isakoff, Jeffrey Hyams, Andrea Orsey, and Donna Boruchov.
Where is Connecticut Children's Medical Center located?
Connecticut Children's Medical Center is situated at 282 Washington Street, Hartford, CT. It is easily accessible from downtown Hartford by heading south on Washington Street, where you will find the hospital on your left.
Who should I call to ask about financial aid or insurance network?
Connecticut Children's Medical Center provides patient financial assistance for those unable to afford treatment, offering free or reduced-cost care through their Patient Financial Services department. They assist families in navigating billing and medical insurance processes. For detailed information on collection policies and procedures, refer to the provided PDF documents.
What insurance does Connecticut Children's Medical Center accept?
Connecticut Children's Medical Center accepts a variety of insurance plans, including Aetna, Blue Cross Blue Shield of CT, Cigna, ConnectiCare, and Healthcare Value Management (HCVM). There is also a network agreement with Aetna Better Health. For the most accurate and up-to-date information on insurance acceptance, please contact the hospital directly or visit their official website.
What awards or recognition has Connecticut Children's Medical Center received?
Connecticut Children's Medical Center, located in Hartford, Connecticut, is renowned for its nursing excellence, holding the prestigious Magnet® designation from the American Nurses Credentialing Center. The hospital's Research Institute is at the forefront of pediatric medicine, conducting groundbreaking clinical trials and innovative research across three key areas: basic & translational research, population health & outcomes research, and clinical research.